

S/N Unknown

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Laurent Lecanu et al.	Examiner:	Unknown
Serial No.:	Unknown	Group Art Unit:	Unknown
Filed:	April 12, 2005	Docket:	1941.001US1
Title:	USE OF (4-ALKYLPYPERAZINYL)(PHENYL) METHANONES IN THE TREATMENT OF ALZHEIMER'S DISEASE		

INFORMATION DISCLOSURE STATEMENT

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicants respectfully request that this Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicants request that a copy of the 1449 form, initialed as being considered by the Examiner, be returned to the Applicants with the next official communication.

Pursuant to 37 C.F.R. §1.97(b), it is believed that no fee or statement is required with the Information Disclosure Statement. However, if an Office Action on the merits has been mailed, the Commissioner is hereby authorized to charge the required fees to Deposit Account No. 19-0743 in order to have this Information Disclosure Statement considered.

Pursuant to 37 C.F.R. 1.98(a)(2), Applicant believes that copies of cited U.S. Patents and Published Applications, and Non-Published Applications identifiable by USPTO Serial Number, are no longer required to be provided to the Office. Notification of this change to this effect was provided in the United States Patent and Trademark Office OG Notices dated October 12, 2004 and October 19, 2004. Thus, Applicant has not included copies of any US Patents or US Patent Applications identifiable by serial number that may be cited with this submission. Should the Office require copies to be provided, Applicant respectfully requests that notice of such requirement be directed to Applicant's below-signed representative. Applicant acknowledges the requirement to submit copies of foreign patent documents and non-patent literature in accordance with 37 C.F.R. 1.98(a)(2).

The Examiner is invited to contact the Applicants' Representative at the below-listed telephone number if there are any questions regarding this communication.

Respectfully submitted,

LAURENT LECANU ET AL.

By their Representatives,

SCHWEGMAN, LUNDBERG, WOEISSNER & KLUTH, P.A.
P.O. Box 2938
Minneapolis, MN 55402
(612) 373-6905

Date Oct. 13, 2006

By Monique M. Perdok Shonka
Monique M. Perdok Shonka
Reg. No. 42,989

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being filed using the USPTO's electronic filing system EFS-Web, and is addressed to: MIS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this 13 day of October 2006.

John P. Gustin-Woodhull
Name

John P. Gustin-Woodhull
Signature

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Under the Patent Reform Act of 1995, no persons are required to respond to a collection of information when it contains a valid OMB control number.

Complete if Known

Application Number	Unknown
Filing Date	April 12, 2005
First Named Inventor	Lecanu, Laurent
Group Art Unit	Unknown
Examiner Name	Unknown

Sheet 1 of 2

Attorney Docket No: 1941.001US1

US PATENT DOCUMENTS

Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Filing Date if Appropriate
	US-20040034019A1	02/19/2004	Tomlinson, R., et al.	08/08/2002
	US-5,693,804	12/02/1997	DeBernardis, J. F., et al.	11/17/1994

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	T*
	DE-2304155	08/01/1974	Ichthyol-Gesellschaft, C.	
	WO-0107435A2	02/01/2001	Botcher, H., et al.	
	WO-04035558A1	04/29/2004	Ancilff, R., et al.	
	WO-04108666A2	12/16/2004	Lecanu, L., et al.	
	WO-05108378A2	11/17/2005	Lecanu, L., et al.	
	WO-2005108378A3	11/17/2005	Lecanu, L., et al.	

OTHER DOCUMENTS – NON PATENT LITERATURE DOCUMENTS

Examiner Initial*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume- issue number(s), publisher, city and/or country where published.	T*
		BAZIARD-MOUYSSET, G., et al., "Synthesis and Structure-activity Relationships of Novel Derivatives as Sigma Site-selective Ligands", <u>European Journal of Medicinal Chemistry, Editions Scientifique Elsevier</u> , (1998),339-347	
		CARCELLER, E., et al., "(Pyridylcyanomethyl) Piperazines as Orally Active PAF Antagonists", <u>Journal of Medicinal Chemistry</u> , vol 35 (22), (1992) 4118-4134	
		FUKUSHI, H., et al., "Synthesis and Platelet-Activating Factor (PAF)-Antagonistic Activities of 1,4-Disubstituted Piperazine Derivatives", <u>Chemical and Pharmaceutical Bulletin, Pharmaceutical Society of Japan</u> , (March, 1994),541-550	
		LECANU, L., et al., "Identification, design, synthesis, and pharmacological activity of (4-ethyl-piperazin-1-yl) phenylmethanone derivatives with neuroprotective properties against Beta-amyloid-induced toxicity", <u>Neuropharmacology, Pergamon press</u> , 49(1), (Jul., 2005),86-96	
		YOUNES, S., et al., "Synthesis and Structure-activity Relationships of Novel Arylalkyl 4-benzyl Piperazine Derivatives as Sigma Site Selective Ligands", <u>European Journal of Medicinal Chemistry</u> , vol. 35 (1), (Jan., 2000),107-121	
		YOUNES-EL-HAGE, S., et al., "Synthese et Etude de L'activite Antidepressive D'aryl et Heteroaryl Carboxamides and Antidepressive Activity Study of Aryl and Heteroaryl Carboxamides of Benzylpiperazine", <u>Annales Pharmaceutiques Francaises</u> , vol. 58 (4), (2000),254-259	

EXAMINER**DATE CONSIDERED**

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER Initial if reference considered, whether or not citation is in compliance with MPEP 806. Drawings through citation if not in compliance and not submitted. Include copy of this form with next communication to applicant. * Applicant's unique citation designation number (optional). * Applicant is to place a check mark here if English language translation is attached.

Substitute for form 1449A-PTO

Under the Patent Revision Act of 1992, no person is required to complete a collection of information unless it contains a valid OMB control number.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	Unknown
Filing Date	April 12, 2005
First Named Inventor	Lecanu, Laurent
Group Art Unit	Unknown
Examiner Name	Unknown

Sheet 2 of 2

Attorney Docket No: 1941.001US1

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	†
		YUNG, D. K., et al., "Potential Anti Arrhythmic Agents Synthesis and Pharmacological Evaluation of Some Piperazine and Ethylenediamine Analogs of Procainamine 1 N Propyl-4-Benzoyl Piperazine Hydro Chloride 1 N Butyl-4-Benzoyl Piperazine Hydro Chloride 1 N Propyl-4-Methoxybenzoyl", <u>Journal of Pharmaceutical Sciences</u> , vol 57 (12), (1968),2073-2080	

EXAMINER**DATE CONSIDERED**

Substitute Disclosure Statement Page 3770-1449

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 909. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. † Applicant's unique citation designation number (optional). ‡ Applicant is to place a check mark here if English language Translation is attached.